The overall positive (PPV) and negative predictivevalues (NPV) across the investigated cancer entities (NSCLC, CRC and PaCa) for EpCAM+ taMP were: 79.03% (PPV) and 85.29% (NPV), respectively, with an overall sensitivity of 95.15% and specificity of 52.73%. This evidence concerns the gene EPCAM and colorectal carcinoma.